RU2009114885A - PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID ORAL DRUG FORM FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT - Google Patents

PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID ORAL DRUG FORM FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT Download PDF

Info

Publication number
RU2009114885A
RU2009114885A RU2009114885/15A RU2009114885A RU2009114885A RU 2009114885 A RU2009114885 A RU 2009114885A RU 2009114885/15 A RU2009114885/15 A RU 2009114885/15A RU 2009114885 A RU2009114885 A RU 2009114885A RU 2009114885 A RU2009114885 A RU 2009114885A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
talc
shell
weight
Prior art date
Application number
RU2009114885/15A
Other languages
Russian (ru)
Other versions
RU2418576C2 (en
Inventor
Маргарита Алексеевна Морозова (RU)
Маргарита Алексеевна Морозова
Аллан Герович Бениашвили (RU)
Аллан Герович Бениашвили
Original Assignee
Маргарита Алексеевна Морозова (RU)
Маргарита Алексеевна Морозова
Аллан Герович Бениашвили (RU)
Аллан Герович Бениашвили
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маргарита Алексеевна Морозова (RU), Маргарита Алексеевна Морозова, Аллан Герович Бениашвили (RU), Аллан Герович Бениашвили filed Critical Маргарита Алексеевна Морозова (RU)
Priority to RU2009114885/15A priority Critical patent/RU2418576C2/en
Publication of RU2009114885A publication Critical patent/RU2009114885A/en
Application granted granted Critical
Publication of RU2418576C2 publication Critical patent/RU2418576C2/en

Links

Abstract

1. Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта, включающая в качестве активного компонента тримебутина малеат и целевые вспомогательные вещества, отличающаяся тем, что она содержит эффективное количество тримебутина малеата и в качестве целевых добавок, взятых в количестве 28,5-56,6% от массы действующего вещества, она содержит лактозу, кремний диоксид коллоидный, тальк, кукурузный крахмал, стеарат магния при следующем соотношении ингредиентов, % от массы действующего вещества: ! Тримебутина малеат 43,40-71,50 Лактоза 37,80-12,90 Кремния диоксид коллоидный 1,70-12,90 Тальк 0,80-2,50 Кукурузный крахмал 13,40-1,10 Стеарат магния 2,60-10,70 ! 2. Фармацевтическая композиция по п.1, отличающаяся тем, что она выполнена в виде твердой лекарственной формы. ! 3. Фармацевтическая композиция по п.2, отличающаяся тем, что она выполнена в виде таблеток, покрытых оболочкой. ! 4. Фармацевтическая композиция по п.3, отличающаяся тем, что оболочка составляет до 5% от массы таблетки без оболочки. ! 5. Фармацевтическая композиция по п.4, отличающаяся тем, что оболочка содержит поливиниловый спирт, тальк, полиэтиленгликоль, титана диоксид, приемлемые красители или готовую смесь марки «Opadry II». 1. A pharmaceutical composition for the treatment of diseases of the gastrointestinal tract, comprising as an active component of trimebutin maleate and target excipients, characterized in that it contains an effective amount of trimebutin maleate and as target additives, taken in an amount of 28.5-56.6 % by weight of the active substance, it contains lactose, colloidal silicon dioxide, talc, corn starch, magnesium stearate in the following ratio of ingredients,% by weight of the active substance:! Trimebutin maleate 43.40-71.50 Lactose 37.80-12.90 Silicon colloidal dioxide 1.70-12.90 Talc 0.80-2.50 Corn starch 13.40-1.10 Magnesium stearate 2.60- 10.70! 2. The pharmaceutical composition according to claim 1, characterized in that it is made in the form of a solid dosage form. ! 3. The pharmaceutical composition according to claim 2, characterized in that it is made in the form of coated tablets. ! 4. The pharmaceutical composition according to claim 3, characterized in that the shell is up to 5% by weight of a tablet without a shell. ! 5. The pharmaceutical composition according to claim 4, characterized in that the shell contains polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, acceptable colorants or the finished mixture of the brand "Opadry II".

Claims (5)

1. Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта, включающая в качестве активного компонента тримебутина малеат и целевые вспомогательные вещества, отличающаяся тем, что она содержит эффективное количество тримебутина малеата и в качестве целевых добавок, взятых в количестве 28,5-56,6% от массы действующего вещества, она содержит лактозу, кремний диоксид коллоидный, тальк, кукурузный крахмал, стеарат магния при следующем соотношении ингредиентов, % от массы действующего вещества:1. A pharmaceutical composition for the treatment of diseases of the gastrointestinal tract, comprising as an active component of trimebutin maleate and target excipients, characterized in that it contains an effective amount of trimebutin maleate and as target additives, taken in an amount of 28.5-56.6 % by weight of the active substance, it contains lactose, colloidal silicon dioxide, talc, corn starch, magnesium stearate in the following ratio of ingredients,% by weight of the active substance: Тримебутина малеатTrimebutin Maleate 43,40-71,5043.40-71.50 ЛактозаLactose 37,80-12,9037.80-12.90 Кремния диоксид коллоидныйSilicon Colloidal Dioxide 1,70-12,901.70-12.90 ТалькTalc 0,80-2,500.80-2.50 Кукурузный крахмалCorn starch 13,40-1,1013.40-1.10 Стеарат магнияMagnesium stearate 2,60-10,702.60-10.70
2. Фармацевтическая композиция по п.1, отличающаяся тем, что она выполнена в виде твердой лекарственной формы.2. The pharmaceutical composition according to claim 1, characterized in that it is made in the form of a solid dosage form. 3. Фармацевтическая композиция по п.2, отличающаяся тем, что она выполнена в виде таблеток, покрытых оболочкой.3. The pharmaceutical composition according to claim 2, characterized in that it is made in the form of coated tablets. 4. Фармацевтическая композиция по п.3, отличающаяся тем, что оболочка составляет до 5% от массы таблетки без оболочки.4. The pharmaceutical composition according to claim 3, characterized in that the shell is up to 5% by weight of a tablet without a shell. 5. Фармацевтическая композиция по п.4, отличающаяся тем, что оболочка содержит поливиниловый спирт, тальк, полиэтиленгликоль, титана диоксид, приемлемые красители или готовую смесь марки «Opadry II». 5. The pharmaceutical composition according to claim 4, characterized in that the shell contains polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, acceptable colorants or the finished mixture of the brand "Opadry II".
RU2009114885/15A 2009-04-22 2009-04-22 Pharmaceutical composition in form of hard peroral drug for treatment of gastrointestinal tract diseases RU2418576C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2009114885/15A RU2418576C2 (en) 2009-04-22 2009-04-22 Pharmaceutical composition in form of hard peroral drug for treatment of gastrointestinal tract diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2009114885/15A RU2418576C2 (en) 2009-04-22 2009-04-22 Pharmaceutical composition in form of hard peroral drug for treatment of gastrointestinal tract diseases

Publications (2)

Publication Number Publication Date
RU2009114885A true RU2009114885A (en) 2010-10-27
RU2418576C2 RU2418576C2 (en) 2011-05-20

Family

ID=44041905

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009114885/15A RU2418576C2 (en) 2009-04-22 2009-04-22 Pharmaceutical composition in form of hard peroral drug for treatment of gastrointestinal tract diseases

Country Status (1)

Country Link
RU (1) RU2418576C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536254C1 (en) * 2013-11-26 2014-12-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Retard tablets of trimebutine
RU2740750C1 (en) * 2020-03-27 2021-01-20 Аллан Герович Бениашвили Agent for treating functional gastrointestinal diseases

Also Published As

Publication number Publication date
RU2418576C2 (en) 2011-05-20

Similar Documents

Publication Publication Date Title
DK2273985T3 (en) Capsule for the prevention of cardiovascular diseases
JP2006516570A5 (en)
RU2015151938A (en) TABLETABLE MEDICINE (4'-TRIFFORMETHYLPHENYL) AMID (Z) -2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID WITH IMPROVED STABILITY
RU2014115287A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH MASKED TASTE AND METHOD FOR PRODUCING IT
EP3150201A1 (en) Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation
RU2011134964A (en) PHARMACEUTICAL COMPOSITION CONTAINING ALEGLITAZAR
RU2009114885A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID ORAL DRUG FORM FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT
RU2013126056A (en) COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS)
RU2008115582A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE
RU2006104035A (en) SOLID MEDICINAL FORM OF DIINDOLYLMETHANE FOR THE TREATMENT OF NEOPLASTIC DISEASES
RU2012136190A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ARTHROZOARTHRITIS CONTAINING REBAMIPID AS AN ACTIVE INGREDIENT
RU2677649C2 (en) Pharmaceutical compositions of montelucast and levocetirisine
US20170151244A1 (en) Oral pharmaceutical composition of tofacitinib
RU2009132616A (en) PHARMACEUTICAL COMPOSITION OF LONG-TERM ACTION FOR CORRECTION OF PSYCHOSOMATIC MANIFESTATIONS
RU2008147739A (en) COMBINED ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION
RU2707286C1 (en) Pharmaceutical antifungal composition based on a chlorophenylbutanedione derivative and a method for production thereof
RU2009101126A (en) PHARMACEUTICAL COMPOSITION WITH ANTIPSYCHOTIC ACTION
RU2580303C1 (en) Composition of pellet drug with proroxanum active ingredient
RU2009134909A (en) COMBINED ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION
RU2005140982A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF PROLIFERATIVE BREAST DISEASES
RU2010134123A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALLERGIC DISEASES
RU2009134910A (en) COMBINED ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION
WO2021053564A1 (en) Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
RU2008113043A (en) PHARMACEUTICAL COMPOSITION WITH ANTI-MIRACLE ACTION
RU2005125959A (en) SOLID MEDICINAL FORM FOR VAGINAL USE, INCLUDING ITRAKONAZOLE

Legal Events

Date Code Title Description
QB4A Licence on use of patent

Free format text: LICENCE

Effective date: 20110805

PC41 Official registration of the transfer of exclusive right

Effective date: 20120926

QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20110805

Effective date: 20130110

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: LICENCE FORMERLY AGREED ON 20110805

Effective date: 20170629

PC41 Official registration of the transfer of exclusive right

Effective date: 20170731

QB4A Licence on use of patent

Free format text: LICENCE

Effective date: 20170802

QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20170802

Effective date: 20180802

PD4A Correction of name of patent owner
QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20170802

Effective date: 20210630